Novo Nordisk’s (NOVOB DC) oral semaglutide demonstrates potential to be the first oral GLP-1 RA for children and adolescents with type 2 diabetes; trial demonstrated a statistically significant and superior reduction in blood sugar by 0.83% vs placebo